Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ardian Targets 2011 For First Launch Of RF Catheter That Treats Hypertension

This article was originally published in The Gray Sheet

Executive Summary

Ardian plans to introduce the first catheter-based treatment for uncontrolled hypertension in Europe by 2011 and in the U.S. by 2013

You may also be interested in...



Randomized Trials Underway For Renal Denervation To Treat Hypertension

Ardian is moving forward with a prospective randomized clinical trial to study its Symplicity radiofrequency catheter for ablation of the sympathetic renal nerves to treat chronic hypertension, following successful results of its first-in-man study

Randomized Trials Underway For Renal Denervation To Treat Hypertension

Ardian is moving forward with a prospective randomized clinical trial to study its Symplicity radiofrequency catheter for ablation of the sympathetic renal nerves to treat chronic hypertension, following successful results of its first-in-man study

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009

Highlights from the Q1 2009 review of medical device and in vitro diagnostics/research dealmaking. Device financing activity remained down bringing in only $522 million--the majority invested through VCs, mostly via late-stage venture rounds--not much change from the previous quarter, but a significant drop from Q1 2008, which saw $920 million. Device M&A brought in $4.4 billion, double the previous quarter, but most of Q1's money came from Abbott's $2.86 billion purchase of Advanced Medical Optics. Four other transactions topped the $200 million mark, including three deals by device giant Medtronic, which grabbed cardio companies CoreValve, Ventor Technologies, and Ablation Frontiers. There was also a decline in in vitro diagnostics and research fund-raising with 2009's opening quarter only seeing about half the dollars of Q4 2008.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel